Global Basal Insulin (Long-Acting Insulin) Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Basal Insulin (Long-Acting Insulin) Market Research Report 2024
Long-acting insulins are also called basal or background insulins. The role of basal insulin, also known as background insulin, is to keep blood glucose levels at consistent levels during periods of fasting. When fasting , the body steadily releases glucose into the blood to our cells supplied with energy.
According to Mr Accuracy reports’s new survey, global Basal Insulin (Long-Acting Insulin) market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Basal Insulin (Long-Acting Insulin) market research.
Key manufacturers engaged in the Basal Insulin (Long-Acting Insulin) industry include Novo Nordisk, Sanofi Aventis, Eli Lilly, Biocon, Julphar, Exir, Sedico and Wockhardt, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Basal Insulin (Long-Acting Insulin) were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Basal Insulin (Long-Acting Insulin) market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Basal Insulin (Long-Acting Insulin) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Novo Nordisk
Sanofi Aventis
Eli Lilly
Biocon
Julphar
Exir
Sedico
Wockhardt
Segment by Type
Lantus
Levemir
Tresiba
Toujeo
Basaglar
Biosimilar Glargines
Type 1 Diabetes
Type 2 Diabetes
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Basal Insulin (Long-Acting Insulin) report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global Basal Insulin (Long-Acting Insulin) market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Basal Insulin (Long-Acting Insulin) market research.
Key manufacturers engaged in the Basal Insulin (Long-Acting Insulin) industry include Novo Nordisk, Sanofi Aventis, Eli Lilly, Biocon, Julphar, Exir, Sedico and Wockhardt, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Basal Insulin (Long-Acting Insulin) were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Basal Insulin (Long-Acting Insulin) market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Basal Insulin (Long-Acting Insulin) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Novo Nordisk
Sanofi Aventis
Eli Lilly
Biocon
Julphar
Exir
Sedico
Wockhardt
Segment by Type
Lantus
Levemir
Tresiba
Toujeo
Basaglar
Biosimilar Glargines
Segment by Application
Type 1 Diabetes
Type 2 Diabetes
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Basal Insulin (Long-Acting Insulin) report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source